Novo Nordisk (NOVOB DC) does not expect to see a biosimilar of semaglutide in China this year, it is protected until April 2027 in China

Novo Nordisk's announcement regarding the protection of semaglutide until 2027 in China reassures investors about its market position and competitive advantage in a lucrative sector.

Newsquawk StaffPublished On the live feed at 15 more headlines followed before this page went public
Newsquawk headlinesUTC

Johnson Controls International (JCI) Q2 2026 (USD): Adj. EPS 1.19 (exp. 1.12), Revenue 6.1bln (exp. 6.08bln); raises FY26 guidance

US sources familiar with mediation efforts for weeks have been telling NYPost, “we just have to get something on paper.” If this reporting is true (Axios), this is a big step in diplomacy — but certainly doesn’t mean we’re at the finish line

Novo Nordisk (NOVOB DC) does not expect to see a biosimilar of semaglutide in China this year, it is protected until April 2027 in China

American officials tell i24NEWS there is a feeling that we are getting closer to an agreement with Iran - but nothing is final.

Iranian journalist Gholhaki, speaking on the Axios report, says, "details of a potential Iran-US agreement appears to be distant from reality, at least in the nuclear domain"

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

The absence of a biosimilar this year suggests sustained revenue potential without immediate competitive pressures, which could positively impact the company's stock performance as the market factors in delayed competition.

Related headlines

The whole workspace, free to try.

Try it free